Satirical Hims & Hers Shareholder Letter - Future of Pharmacies
Satirical Hims & Hers Shareholder Letter - Future of Pharmacies
TJ Parker (PillPack/Amazon Pharmacy)
💡 Key Learnings from this article
Telehealth + Pharmacy = New Power Players
Old Model: Doctor → Prescription → Pharmacy. New Model: App → AI Consultation → Direct-to-Consumer. Traditional pharmacies are being disintermediated. The future is vertical integration (diagnosis + prescription + dispensing in one app).
Compounding Pharmacies = Major Disruption
Brand-name drugs are expensive. Compounding pharmacies make copies at fraction of cost in regulatory gray zone. Every blockbuster drug will have compounded alternatives. Pharma pricing power erodes but quality/safety concerns rise.
The Fast Follower Pharma Model
Wait for FDA approval → Launch copycat → No R&D costs. This means less incentive for original drug development. Big Pharma may shift to licensing vs direct sales. More M&A to buy innovators before they get copied.
Regulation Will Be the Battleground
Two scenarios: Lax regulation = telehealth boom, more compounding, innovation slows, patient safety risks. Strict enforcement = traditional pharma protected, compounding restricted, R&D incentives preserved, higher prices. FDA next moves shape entire industry.
Consumer Behavior is Changing
Patients want: convenience (home delivery), cash-pay to skip insurance, trust influencers as much as doctors, demand pricing transparency. Future pharmacy = Amazon-like: subscriptions, same-day delivery, price comparison, AI recommendations.
MENA Opportunity
Opportunity: Launch telehealth + pharmacy platforms. Challenge: Regulatory frameworks underdeveloped. Model to watch: Amazon Pharmacy, Hims, Ro. Key success factor: Trust + last-mile delivery. The pharmacy of the future is an app, not a store.
📝 AI Summary
A satirical critique of Hims & Hers business model and compounded GLP-1 medications, revealing insights about the future of pharmacy industry globally.